Skip to content

PDA for Kidneys Study

Development of a Novel Kidney-focused Approach to Treatment of a Patent Ductus Arteriosus (PDA) in Vulnerable Preterm Neonates - A Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06658496
Acronym
PDA4K
Enrollment
45
Registered
2024-10-26
Start date
2024-12-19
Completion date
2027-05-01
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease, Patent Ductus Arteriosus

Keywords

neonate

Brief summary

The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney injury. Researchers will do this by looking at ultrasound images of the heart, analyzing substances in the urine, and evaluating oxygen levels in the kidneys.

Interventions

DEVICENear Infrared Spectroscopy

Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER
The Gerber Foundation
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 7 Days
Healthy volunteers
No

Inclusion criteria

* Delivered at \<32 weeks' gestation * ≤72 hours of age * Inpatient at Meriter Hospital, Inc. NICU * At least one parent/guardian is able to provide parental permission in English or Spanish

Exclusion criteria

* Major congenital anomalies of kidney * Attending physician's discretion to not place NIRS sensors due to clinical concerns * In the PI or Co-I's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life * Birth parent aged \<18

Design outcomes

Primary

MeasureTime frameDescription
Comparison of patent ductus arteriosus (PDA) echocardiography parameters to kidney hypoxiaDays 1 to 7 of ageMeasured through continuous renal near infrared spectroscopy (NIRS) monitoring in neonates with a PDA to those without. Echos will be obtained every 48 hours during the first 7 days of age for a maximum of 3. RSO2 will be recorded until 7 days of age.

Secondary

MeasureTime frameDescription
Correlation of Iowa PDA score to kidney hypoxiaDays 1-7 of ageThe Iowa PDA score will be classified as low (0-3), moderate (4-6), or high volume (\>6) for each echo obtained. Lower scores are optimal. RSO2 correlation will be made with PDA score during the first 7 days of age.
Correlation between urinary biomarkers and Iowa PDA scoreDays 1-7 of lifeThe Iowa PDA score will be classified as low (0-3), moderate (4-6), or high volume (\>6). Urinary NGAL, cystatin C, and beta 2 micro globulin levels will be measured daily for the first 7 days of age and a correlation with the Iowa PDA score to levels of these biomarkers will be made.
Correlation between rates of hypertension and Iowa PDA scoreDuration of hospitalization, up to 6 monthsThe Iowa PDA score will be classified as low (0-3), moderate (4-6), or high volume (\>6). Hypertension will be assessed for throughout hospitalization and a correlation with Iowa PDA score and the diagnosis of hypertension will be made.
Correlation between rates of acute kidney injury (AKI) and Iowa PDA scoreDuration of hospitalization, up to 6 monthsThe Iowa PDA score will be classified as low (0-3), moderate (4-6), or high volume (\>6). The diagnosis of AKI will be made using either or both urine output criteria or serum creatinine criteria and a correlation will be made with the IOWA PDA score in the first 7 days of age.

Countries

United States

Contacts

CONTACTPaige Condit, MD
pcondit@wisc.edu616-481-9914
CONTACTMeg Baker
meg.baker@wisc.edu
PRINCIPAL_INVESTIGATORMatthew Harer, MD

University of Wisconsin, Madison

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026